Study of EVX-01 Vaccine in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Study Details
Study Description
Brief Summary
The purpose of this single arm, multi-national clinical trial in patients with metastatic or unresectable melanoma is to evaluate the BOR and compare it to historical data on patients on anti-PD1 treatment with pembrolizumab alone.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Patients will initiate treatment with pembrolizumab at the start of the trial and receive up to 18 treatment cycles (approximately 2 years). Immunization with the EVX-01 will be initiated at Week 12. In total, 10 doses of EVX-01 will be administered intramuscularly, with 6 doses given two weeks apart and 4 booster doses at later time points.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: EVX-01 in combination with pembrolizumab EVX-01 is administered im. Pembrolizumab is administered according to label |
Drug: EVX-01
Investigational drug given in combination with standard of care
Drug: Pembrolizumab 25 MG/ML
Standard of care
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Change in the best overall response (BOR) [Measurements at Baseline through study completion (up to 102 weeks)]
Composite of a BOR of complete response (CR) or PR for patients with SD at the time of first EVX-01 administration and a BOR of CR for patients with PR at the time of first EVX-01 administration, within 2 years of treatment with pembrolizumab, as per RECIST 1.1 criteria
Secondary Outcome Measures
- Change in overall response rate [Measurements at Baseline through study completion (up to 102 weeks)]
Overall response rate, defined as the proportion of the patients who have best response as CR or PR assessed 2 years after initiation of treatment with pembrolizumab, as per RECIST 1.1 criteria
- Change in progression free survival (PFS) [Measurements at Baseline through study completion (up to 102 weeks)]
PFS in patients with an assessment of SD, PR, or CR at the time of first EVX-01 administration, assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from the first EVX-01 administration to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first
- Change in overall survival (OS) [Measurements at Baseline through study completion (up to 102 weeks)]
OS assessed 2 years after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause
- Number, type and severity of adverse events (AEs) and serious adverse events (SAEs) [Measurements at Baseline through study completion (up to 102 weeks)]
Number, type and severity of adverse events (AEs) and serious adverse events (SAEs) to evaluate the safety of EVX-01 in patients with metastatic or unresectable melanoma on pembrolizumab treatment
- Immunologic response induced by EVX-01 [Measurements at Baseline through study completion (up to 102 weeks)]
Activation and level of neoepitope specific CD4+ and CD8+ T-cells before, during and after EVX-01 immunization
- Percentage of patients in which EVX-01 is generated, produced, and administered [From tumor biopsy sampling to first dose of EVX-01 (up to 16 weeks)]
Percentage of patients in which EVX-01 is generated, produced, and administered to evaluate the manufacturing feasibility of EVX-01
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Be at least 18 years of age on day of signing informed consent.
-
Histologically confirmed, and not amenable to local therapy, metastatic or unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.
-
Patient may not have a diagnosis of uveal or ocular melanoma.
-
Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
-
Patients must have testing for a BRAF mutation prior to study entry.
Note: Patients with BRAF V600E mutant melanoma may have received prior BRAF inhibitor therapy as first-line systemic therapy and be eligible for this study as second line treatment. At the discretion of the investigator, patients with BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor are also eligible for this study as first line treatment if they meet the following additional criteria:
- LDH < local ULN, ii. No clinically significant tumor related symptoms in the judgment of the investigator, and iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator
-
Have measurable disease per RECIST 1.1 as assessed by the local site investigator within 4 weeks prior to the first visit. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
-
Patients must be willing and able to provide fresh or frozen tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses. If a sufficient amount of tumor tissue from an unresectable or metastatic site is not available prior to the start of the screening phase, subjects must consent to allow the acquisition of additional tumor tissue. In addition, participants may provide additional biopsy at the time of discontinuation due to progression.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion Criteria:
-
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
-
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
-
Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
-
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention. Note: Administration of killed vaccines are allowed.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Melanoma Institute Australia | Wollstonecraft | New South Wales | Australia | 2065 |
| 2 | One Clinical Research | Nedlands | Western Australia | Australia | 6009 |
| 3 | Sir Charles Gairdner Hospital | Nedlands | Western Australia | Australia | 6009 |
Sponsors and Collaborators
- Evaxion Biotech A/S
- Merck Sharp & Dohme LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- EVX-01-001
- KEYNOTE KN-D36